Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Revolution Medicines (NASDAQ: RVMD) and raised the price target from $240 to $241. This adjustment reflects a positive outlook for the company in the market.